MicroRNA signatures from multidrug‑resistant Mycobacterium tuberculosis

Ren,Na; Gao,Guiju; Sun,Yue; Zhang,Ling; Wang,Huizhu; Hua,Wenhao; Wan,Kanglin; Li,Xingwang

doi:10.3892/mmr.2015.4262

MicroRNA signatures from multidrug‑resistant Mycobacterium tuberculosis

Authors:
- Na Ren
- Guiju Gao
- Yue Sun
- Ling Zhang
- Huizhu Wang
- Wenhao Hua
- Kanglin Wan
- Xingwang Li
View Affiliations

Affiliations: The National Clinical Key Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, P.R. China, Department of Infectious Diseases, First Hospital of Tsinghua University, Beijing 100016, P.R. China, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, State Key Laboratory for Infectious Disease Prevention and Control, Beijing 102206, P.R. China
Published online on: August 28, 2015 https://doi.org/10.3892/mmr.2015.4262
Pages: 6561-6567
Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tuberculosis (TB) infections, caused by multidrug‑resistant Mycobacterium tuberculosis (MDR MTB), remain a significant public health concern worldwide. The regulatory mechanisms underlying the emergence of MDR MTB strains remain to be fully elucidated, and further investigation is required in order to develop better strategies for TB control. The present study investigated the expression profile of microRNA (miRNA) in MTB strains, and examined the differences between sensitive MTB and MDR MTB using next generation sequencing (NGS) with Illumina Deep Sequencing technology to better understand the mechanisms of resistance in MDR MTB, A total of 5, 785 and 195, and 6, 290 and 595 qualified Illumina reads were obtained from two MDR MTB strains, and 6, 673 and 665, and 7, 210 and 217 qualified Illumina reads were obtained from two sensitive MTB strains. The overall de novo assembly of miRNA sequence data generated 62 and 62, and 95 and 112 miRNAs between the 18 and 30 bp long from sensitive MTB strains and MDR MTB strains, respectively. Comparative miRNA analysis revealed that 142 miRNAs were differentially expressed in the MDR MTB strain, compared with the sensitive MTB strain, of which 48 were upregulated and 94 were downregulated. There were six similarly expressed miRNAs between the MDR and sensitive MTB strains, and 108 miRNAs were expressed only in the MDR MTB strain. The present study acquired miRNA data from sensitive MTB and MDR MTB strains using NGS techniques, and this identification miRNAs may serve as an invaluable resource for revealing the molecular basis of the regulation of expression associated with the mechanism of drug‑resistance in MTB.

View Figures

View References

1	World Health Organization (WHO): Global Tuberculosis Control Report 2010. WHO; Geneva: 2010
2	US Agency for International Development: Report to congress: Health-related research and development activities at USAID-an update on the five-year strategy, 2006–2010. US Agency for International Development. 182:1788–1790. 2009.
3	Tare P, China A and Nagaraja V: Distinct and contrasting transcription initiation patterns at Mycobacterium tuberculosis promoters. PLoS One. 7:e439002012. View Article : Google Scholar : PubMed/NCBI
4	Jia Y and Patel SS: Kinetic mechanism of transcription initiation by bacteriophage T7 RNA polymerase. Biochemistry. 36:4223–4232. 1997. View Article : Google Scholar : PubMed/NCBI
5	Martínez-Antonio A, Salgado H, Gama-Castro S, et al: Environmental conditions and transcriptional regulation in Escherichia coli: A physiological integrative approach. Biotechnol Bioeng. 84:743–749. 2003. View Article : Google Scholar
6	Holley CL and Topkara VK: An introduction to small non-coding RNAs: miRNA and snoRNA. Cardiovas Drugs Ther. 25:151–159. 2011. View Article : Google Scholar
7	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
8	Baroni D and Arrigo P: MicroRNA target and gene validation in viruses and bacteria. Methods Mol Biol. 1107:223–231. 2014. View Article : Google Scholar
9	Chinese Medical Association: TB volume of clinical diagnosis and treatment guidelines. People's Medical Publishing House; Beijing: 2005
10	World Medical Association: World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 310:2191–2194. 2013. View Article : Google Scholar : PubMed/NCBI
11	Huard RC, Lazzarini LC, Butler WR, van Soolingen D and Ho JL: PCR-based method to differentiate the subspecies of the Mycobacterium tuberculosis complex on the basis of genomic deletions. J Clin Microbiol. 41:1637–1650. 2003. View Article : Google Scholar : PubMed/NCBI
12	Bao X, Lian L, Xu D, et al: Rapid species identification of 391 clinical Mycobacterium isolates from Anhui province by multi-locus PCR. Chinese Journal of Zoonoses. 28:659–663. 2012.
13	Kozomara A and Griffiths-Jones S: miRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39:D152–D157. 2011. View Article : Google Scholar :
14	Martin M: Cutadapt removes adaptor sequences from high-throughput sequencing reads. EMBnetjournal. 17:10–12. 2011.
15	Langmead B, Trapnell C, Pop M and Salzberg SL: Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10:R252009. View Article : Google Scholar : PubMed/NCBI
16	Wojcicka A, Swierniak M, Kornasiewicz O, et al: Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma. Int J Biochem Cell Biol. 53:208–217. 2014. View Article : Google Scholar : PubMed/NCBI
17	Nielsen CB, Shomron N, Sandberg R, Hornstein E, Kitzman J and Burge CB: Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA. 13:1894–1910. 2007. View Article : Google Scholar : PubMed/NCBI
18	World Health Organization (WHO): Global tuberculosis report, 2012. WHO; Geneva: 2012
19	Dye C, Espinal MA, Watt CJ, Mbiaga C and Williams BG: Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis. 185:1197–1202. 2002. View Article : Google Scholar : PubMed/NCBI
20	Raviglione MC, Gupta R, Dye CM and Espinal MA: The burden of drug-resistant tuberculosis and mechanisms for its control. Ann NY Acad Sci. 953:88–97. 2001. View Article : Google Scholar
21	Zumia A and Grange JM: Multidrug-resistant tuberculosis - can the tide be turned? Lancet Infect Dis. 1:199–202. 2001. View Article : Google Scholar
22	World Health Organization (WHO): Anti-tuberculosis drug resistance in the world: The WHO/IUATLD global project on anti-tuberculosis drug resistance suveillance: Third global report. WHO; Geneva: 2003
23	Banerjee R, Rudra P, Prajapati RK, Sengupta S and Mukhopadhyay J: Optimization of recombinant Mycobacterium tuberculosis RNA polymerase expression and purification. Tuberculosis (Edinb). 94:397–404. 2014. View Article : Google Scholar
24	Artsimovitch I, Vassylyeva MN, Svetlov D, et al: Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell. 122:351–363. 2005. View Article : Google Scholar : PubMed/NCBI
25	Campbell EA, Korzheva N, Mustaev A, et al: Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 104:901–912. 2001. View Article : Google Scholar : PubMed/NCBI
26	Feklistov A, Mekler V, Jiang Q, et al: Rifamycins do not function by allosteric modulation of binding of Mg²⁺ to the RNA polymerase active center. Proc Natl Acad Sci USA. 105:14820–14825. 2008. View Article : Google Scholar
27	Chopra I: Bacterial RNA polymerase: A promising target for the discovery of new antimicrobial agents. Curr Opin Investig Drugs. 8:600–607. 2007.PubMed/NCBI
28	Chopra I, Hesse L and O'Neill AJ: Exploiting current understanding of antibiotic action for discovery of new drugs. Symp Ser Soc Appl Microbiol. (31): 4S–15S. 2002. View Article : Google Scholar : PubMed/NCBI
29	Darst SA: New inhibitors targeting bacterial RNA polymerase. Trends Biochem Sci. 29:159–160. 2004. View Article : Google Scholar : PubMed/NCBI
30	Villain-Guillot P, Bastide L, Gualtieri M and Leonetti JP: Progress in targeting bacterial transcription. Drug Discov Today. 12:200–208. 2007. View Article : Google Scholar : PubMed/NCBI
31	Zhang J, Chiodini R, Badr A and Zhang G: The impact of next-generation sequencing on genomics. J Genet Genomics. 38:95–109. 2011. View Article : Google Scholar : PubMed/NCBI
32	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
33	Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114. 2008. View Article : Google Scholar : PubMed/NCBI
34	Lim LP, Lau NC, Garrett-Engele P, et al: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
35	Jazdzewski K, Boguslawska J, Jendrzejewski J, et al: Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab. 96:E546–E553. 2011. View Article : Google Scholar